Down 15% pre-market on XETRA: FYB.DE Formycon AG 20 Mar 2026 earnings risk

FYB.DE stock opened the pre-market session on XETRA down 15.14%, trading at €16.82 on 20 Mar 2026 after a heavy sell-off from an opening price of €19.34. Volume is elevated at 42,312 shares versus an average of 17,193, signaling outsized selling pressure in Germany’s biotech segment. The drop comes with an earnings date on 26 Mar 2026 and renewed investor focus on trial timelines and valuation multiples.

FYB.DE stock: intraday move, volume and immediate catalysts

Formycon AG (FYB.DE) lost €3.00 in pre-market trade, from €19.82 to €16.82, a -15.14% one-day move on XETRA. The candle shows a low at €16.82 and a high at €19.50 for the session. Elevated volume at 42,312 (rel. vol 2.46) suggests stop-driven selling and active position rebalancing ahead of the company earnings announcement on 26 Mar 2026.

FYB.DE stock: fundamentals and valuation snapshot

Formycon reports EPS of -9.66 and a negative PE of -1.74, reflecting sizable losses as R&D-heavy biotech. Key ratios show price-to-book 0.73 and price-to-sales 5.74. Market cap stands at €297,258,178, and the current ratio is 1.54, indicating short-term liquidity is adequate while profitability remains weak.

FYB.DE stock: technicals and momentum signal the oversold condition

Technical indicators show FYB.DE is oversold: RSI 28.21, MACD histogram -0.20, and Williams %R -100.00. The 50-day average is €22.62 and the 200-day average is €24.33, highlighting the downtrend. Bollinger lower band sits at €17.33, close to the session low, suggesting a possible short-term bounce but continued downside risk until momentum stabilizes.

FYB.DE stock: Meyka AI grade and model forecasts

Meyka AI rates FYB.DE with a score out of 100: 64.78 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly level of €17.49 (+3.95% vs current €16.82) and a yearly target of €9.50 (-43.53%). Forecasts are model-based projections and not guarantees.

FYB.DE stock: risk drivers and upcoming catalysts

Primary risks include Phase III trial readouts for FYB202/FYB203, regulatory review timelines, and the upcoming earnings report on 26 Mar 2026. Secondary risks are funding needs and commercial partner deals. Positive catalysts would be clear trial progress, licensing agreements, or stronger-than-expected revenues in the quarterly report.

FYB.DE stock: trading setup, price targets and scenario planning

Near-term support is €16.82 with resistance at the open €19.34 and the 50-day €22.62. Scenario price targets: base case €17.50 (short-term stabilisation), bear case €9.50 (Meyka yearly forecast), and bull case €28.00 (recovery toward mid-year highs). Traders should size positions for volatility and use stop-losses given the RSI and ATR €1.13.

Final Thoughts

FYB.DE stock is trading as a top pre-market loser on 20 Mar 2026, down 15.14% to €16.82 on XETRA as investors brace for earnings and clinical updates. Fundamentals show negative EPS -9.66 and a negative PE -1.74, while valuation metrics like PB 0.73 and P/S 5.74 point to mixed signals: balance-sheet strength but weak profitability. Meyka AI’s forecast model projects €17.49 for the next month (+3.95% vs current price) and €9.50 at 12 months (-43.53%). These imply a narrow near-term upside but a material downside risk if clinical or earnings results disappoint. Given the March 26, 2026 earnings date, we see a risk-first trading environment: short-term traders can target the €17.50 base case and protect positions with tight stops, while longer-term investors should await clearer trial and revenue signals. Meyka AI — an AI-powered market analysis platform — flags this as high-volatility, event-driven equity; forecasts are model outputs and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.